Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States

por Wang-Gillam, Andrea, Schelman, William, Ukrainskyj, Stacey, Chien, Caly, Gonzalez, Martha, Yang, Zhao, Kania, Marek, Yeckes-Rodin, Heather
Publicado 2023

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

por Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John C., Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.
Publicado 2018